Asbjørn Hróbjartsson

Datos Biográficos

ID4889093
NOMBREAsbjørn Hróbjartsson
NOMBRESAsbjørn
APELLIDOHróbjartsson
FIRMAHRÓBJARTSSON A
AFILIACIONESUniversity of Southern Denmark
ORCID0000-0002-2451-5012
VERIFICADOSí
TOTAL DE OBRAS13
TOTAL DE CITAS0
TOTAL COMO AUTOR13
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2013
AÑO MÁS RECIENTE DE PUBLICACIÓN2023
ÍNDICE H0

  • Meta-epidemiology and the MetaBLIND study

    Open AccessHelene Moustgaard, Asbjørn HróbjartssonARTICLEJournal of Health Psychology2023Referencias: 9

    In 2020 we published MetaBLIND, a large meta-epidemiological study on the impact of masking on effect estimates in randomized clinical trials (RCTs). While masking is an established methodological practice in RCTs it is not clear to what extent results of non-masked RCTs are biased. Surprisingly, we found no evidence of an impact of masking on effect estimates, on average. Michiel Tack commented on the MetaBLIND study, and here we respond. The is…

  • A declaração PRISMA 2020

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLERevista Panamericana de Salud…2022

    A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodologia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração d…

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEPLoS Medicine2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEJournal of Clinical Epidemiology2021

  • Declaración PRISMA 2020

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLERevista Española de Cardiología…2021

    La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La…

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEInternational Journal of Surgery2021

  • PRISMA 2020 explanation and elaboration

    Open AccessMatthew J Page, David Moher et al.ARTICLEBMJ2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEBMJ2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLESystematic Reviews2021

  • The PRISMA 2020 statement

    Matthew J Page, Joanne Mckenzie et al.PREPRINT2020

    Background: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did and what they found. Over the last decade, there have been many advances in systematic review methodology and terminology, which have necessitated an update to the guideline.Objectives: To develop the PRISMA 2020 statem…

  • RoB 2

    Open AccessJonathan Sterne, Jelena Savović et al.ARTICLEBMJ2019

    Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.

  • Robins-I

    Open AccessJonathan Sterne, Jonathan AC Sterne et al.ARTICLEBMJ2016

    Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that d…

  • SPIRIT 2013 Statement

    Open AccessAn-Wen Chan, An‐Wen Chan et al.ARTICLEAnnals of Internal Medicine2013

    The protocol of a clinical trial serves as the foundation for study planning, conduct, reporting, and appraisal. However, trial protocols and existing protocol guidelines vary greatly in content and quality. This article describes the systematic development and scope of SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013, a guideline for the minimum content of a clinical trial protocol.The 33-item SPIRIT checklist app…